OUR STRATEGY

Performance against Strategy

OUR STRATEGY

Performance against Strategy

The seven SANBS Strategic objectives are clearly defined and designed to achieve our vision.

Performance against our strategic priorities is measured through defined KPIs incorporated into an overall “iHEALTh” balanced scorecard which cascades down to all levels within the organisation.


In reflecting on the achievements over the past year, these are celebrated, as the Covid-19 pandemic continued to impact on SANBS operations during the 2021/2022 financial year and the past 12 months continued to be challenging.  We had to constantly monitor our internal and external environment and be agile in our responses, adapt how we work and made tweaks to our business model to ensure a safe environment for donors and staff whilst maintaining our supply of blood products to meet demand.

 

In the tables below is a summary of our performance for the period ending 31 March 2022 against each component of our iHEALTh scorecard. 

The seven SANBS Strategic objectives are clearly defined and designed to achieve our vision.

Performance against our strategic priorities is measured through defined KPIs incorporated into an overall “iHEALTh” balanced scorecard which cascades down to all levels within the organisation.


In reflecting on the achievements over the past year, these are celebrated, as the Covid-19 pandemic continued to impact on SANBS operations during the 2021/2022 financial year and the past 12 months continued to be challenging.  We had to constantly monitor our internal and external environment and be agile in our responses, adapt how we work and made tweaks to our business model to ensure a safe environment for donors and staff whilst maintaining our supply of blood products to meet demand.

 

In the tables below is a summary of our performance for the period ending 31 March 2022 against each component of our iHEALTh scorecard. 

INNOVATION

Aspiration

  • Improve and expand current products and services through innovation

Strategic Priorities

  • Unlock other revenue streams-enhance services and innovative product mix
  • Lead the development, commercialisation and delivery of cellular therapies

FY22 Highlights

  • Alternative revenue returned to pre Covid-19 levels due to significant increase in cellular therapy footprint
  • Number of publications doubled the number of target
  • CAA approved SANBS’s licence to deploy drones
  • SARS-CoV-2 sero prevalence study contributing to public health knowledge on Covid-19
  • Increased donor base compared to 2021

Contribution to Long-term Sustainable Value

Related Material
Matters

  • Meeting blood demand
  • Future changing world
    • remarkable research and publications
    • new donor vehicles
    • smart fridges
    • Mount Edgecombe building

INNOVATION

Aspiration

  • Improve and expand current products and services through innovation

Strategic Priorities

  • Unlock other revenue streams-enhance services and innovative product mix
  • Lead the development, commercialisation and delivery of cellular therapies

FY22 Highlights

  • Alternative revenue returned to pre Covid-19 levels due to significant increase in cellular therapy footprint
  • Number of publications doubled the number of target
  • CAA approved SANBS’s licence to deploy drones
  • SARS-CoV-2 sero prevalence study contributing to public health knowledge on Covid-19
  • Increased donor base compared to 2021

Contribution to Long-term Sustainable Value

Related Material
Matters

  • Meeting blood demand
  • Future changing world
    • remarkable research and publications
    • new donor vehicles
    • smart fridges
    • Mount Edgecombe building

Reflecting on our performance against the 2021/2022 Scorecard and how we added value

Target achieved/exceeded New initiative on track against current plan (no concerns Improvements YOY No Concerns yet Below Target

Reflecting on our performance against the 2021/2022 Scorecard and how we added value

Target achieved/exceeded New initiative on track against current plan (no concerns Improvements YOY No Concerns yet Below Target

Below, we further unpack the various components of our performance against our iHEALTh strategy

Key Measured Initiatives

Below, we further unpack the various components of our performance against our iHEALTh strategy

Key Measured Initiatives

Alternative revenue

Target

  • R66m

IR 2021

  • R64.6m

Progress for FY22

  • R69.97m
  • Teams introduced a number of new services

target for 2022/2023

  • R76m
  • An increased focus on stem cell and organ transplant work which reduced during Covid-19

Alternative revenue

Target

  • R66m

IR 2021

  • R64.6m

Progress for FY22

  • R69.97m
  • Teams introduced a number of new services

target for 2022/2023

  • R76m
  • An increased focus on stem cell and organ transplant work which reduced during Covid-19

#Translational Research Office

Target

  • 10

IR 2021

  • 19

Progress for FY22

  • 20

target for 2022/2023

  • 11
  • Further expand multiple national and international collaborations

#Translational Research Office

Target

  • 10

IR 2021

  • 19

Progress for FY22

  • 20

target for 2022/2023

  • 11
  • Further expand multiple national and international collaborations

RAD Academy

Target

  • Successful launch

IR 2021

  • Upgraded digital learning platform
  • Blood transfusion science included in tertiary curriculum

Progress for FY22

  • Progress with Senior Leadership Immersive programme and management programmes with Wits

target for 2022/2023

  • Advance Dual Career path optionality
  • Expanding in some aspects to Africa (advisory – Botswana and Ghana – also proficiency programmes – links to CSR)
  • Progress – webinars and learning cafes (internal and external using technology – extensive outreach)

RAD Academy

Target

  • Successful launch

IR 2021

  • Upgraded digital learning platform
  • Blood transfusion science included in tertiary curriculum

Progress for FY22

  • Progress with Senior Leadership Immersive programme and management programmes with Wits

target for 2022/2023

  • Advance Dual Career path optionality
  • Expanding in some aspects to Africa (advisory – Botswana and Ghana – also proficiency programmes – links to CSR)
  • Progress – webinars and learning cafes (internal and external using technology – extensive outreach)

Drone Project

Target

  • Project plan

IR 2021

  • 4 drones secured

Progress for FY22

  • Civil Aviation Authority (CAA) approved SANBS’ licence to deploy drones

target for 2022/2023

  • Commence ICASA certification for new drones
  • Train SANBS and hospital staff
  • Start flying blood products in accordance with CAA approved operations manual
  • Approval to deploy from Sebokeng to Katlehong hospital

Drone Project

Target

  • Project plan

IR 2021

  • 4 drones secured

Progress for FY22

  • Civil Aviation Authority (CAA) approved SANBS’ licence to deploy drones

target for 2022/2023

  • Commence ICASA certification for new drones
  • Train SANBS and hospital staff
  • Start flying blood products in accordance with CAA approved operations manual
  • Approval to deploy from Sebokeng to Katlehong hospital

BECS Implementation

Target

  • Project plan

IR 2021

  • Project delays

Progress for FY22

  • Key milestones are closely monitored

target for 2022/2023

  • Commence user acceptance testing and training for the new system
  • Key focus area is change management (training, competence and buy-in)

BECS Implementation

Target

  • Project plan

IR 2021

  • Project delays

Progress for FY22

  • Key milestones are closely monitored

target for 2022/2023

  • Commence user acceptance testing and training for the new system
  • Key focus area is change management (training, competence and buy-in)

SARS-CoV-2 sero prevalence study

Target

  • New project

IR 2021

  • Sero-surveillance study to estimate the prevalence of antibodies to SARS-COV-2
  • Objective was to conduct three sub studies, however due to SAHPRA regulations, reagents could not be obtained

Progress for FY22

  • Wrote pre-print paper for sero -prevalence
  • Completed testing and analysis post the delta wave
  • Commenced longitudinal testing for frequent repeat donors

target for 2022/2023

  • Complete additional testing post Omicron wave
  • Continue enrolment of frequent repeat donors for longitudinal study
  • Testing of samples for the repeat donor study
  • Finalisation and approval of protocol for staff study
  • Analysis and reporting of results
  • Write peer reviewed paper for sero-prevalence

SARS-CoV-2 sero prevalence study

Target

  • New project

IR 2021

  • Sero-surveillance study to estimate the prevalence of antibodies to SARS-COV-2
  • Objective was to conduct three sub studies, however due to SAHPRA regulations, reagents could not be obtained

Progress for FY22

  • Wrote pre-print paper for sero -prevalence
  • Completed testing and analysis post the delta wave
  • Commenced longitudinal testing for frequent repeat donors

target for 2022/2023

  • Complete additional testing post Omicron wave
  • Continue enrolment of frequent repeat donors for longitudinal study
  • Testing of samples for the repeat donor study
  • Finalisation and approval of protocol for staff study
  • Analysis and reporting of results
  • Write peer reviewed paper for sero-prevalence

Smart fridges

Target

  • Project plan

IR 2021

  • First Smart fridge received

Progress for FY22

  • Pilot study underway
  • Validations still in progress

target for 2022/2023

  • Complete validations
  • Rollout of 10 additional smart fridges to hospitals,  primarily in rural areas

Smart fridges

Target

  • Project plan

IR 2021

  • First Smart fridge received

Progress for FY22

  • Pilot study underway
  • Validations still in progress

target for 2022/2023

  • Complete validations
  • Rollout of 10 additional smart fridges to hospitals,  primarily in rural areas

Mobile vehicles

Target

  • Completion of first phase

IR 2021

  •  
  • 6-bed mobile donor centre successfully used

Progress for FY22

  • Progress with design
  • Procured a 4-bed mobile donor centre then evaluation of 3, 4 & 6 bed options to determine optimal fleet configuration

target for 2022/2023

  • Expand the fleet of self-contained mobile vehicles
  • Roll out in FY23 to increase donor convenience

Mobile vehicles

Target

  • Completion of first phase

IR 2021

  •  
  • 6-bed mobile donor centre successfully used

Progress for FY22

  • Progress with design
  • Procured a 4-bed mobile donor centre then evaluation of 3, 4 & 6 bed options to determine optimal fleet configuration

target for 2022/2023

  • Expand the fleet of self-contained mobile vehicles
  • Roll out in FY23 to increase donor convenience

NAVIGATE TO:

NAVIGATE TO:

How can we help you?

Let's Connect

Head Office

  • 1 Constantia Boulevard Constantia Kloof, Roodepoort, 1709
  • (011) 761-9000
  • customerservice@sanbs.org.za

Main Links

Ⓒ 2022 - All Rights Are Reserved. SANBS Integrated Report. Created by Joshero (Pty) Ltd.

Head Office

  • 1 Constantia Boulevard Constantia Kloof, Roodepoort, 1709
  • (011) 761-9000
  • customerservice@sanbs.org.za

Main Links

Ⓒ 2022 - All Rights Are Reserved. SANBS Integrated Report. Created by Joshero (Pty) Ltd.